🔬 WHO-GMP Certification for Indian Generics: What the New Schedule M Rules Mean for You
India supplies approximately 20% of the world’s generic medicines by volume, making it the largest provider of affordable generic drugs globally. But with this scale comes a critical question for buyers around the world: How do you know if an Indian generic medicine is safe, effective, and manufactured to international quality standards?
The answer lies in WHO-GMP certification and India’s newly revised Schedule M manufacturing standards — the most significant overhaul of Indian pharmaceutical quality regulations in decades. This article explains what these standards mean for you as a buyer or patient.
🏭 What Is WHO-GMP Certification?
Good Manufacturing Practices (GMP) are the minimum quality standards that pharmaceutical manufacturers must meet to ensure their products are consistently produced and controlled according to quality standards. WHO-GMP certification means a facility has been audited by or complies with standards set by the World Health Organization.
- WHO-GMP covers: raw materials, facility hygiene, equipment calibration, staff training, documentation, and quality control testing
- It is recognized globally — including by the FDA (US), EMA (Europe), and other national regulators
- Indian manufacturers with WHO-GMP certification can export to over 150 countries
- Without WHO-GMP compliance, a generic medicine cannot be sold in most regulated markets
As reported by ClearIAS (March 2026) and The Economic Times, India’s position as the largest generic medicine provider makes adherence to WHO-GMP standards a matter of global public health importance.
🇮🇳 India’s New Schedule M: The Biggest Quality Overhaul Since 1988
Schedule M is the section of India’s Drugs and Cosmetics Rules that lays out GMP requirements for pharmaceutical manufacturers. In 2025-2026, the Indian government implemented the most significant revision of Schedule M in nearly four decades, bringing Indian standards more closely in line with WHO-GMP and international benchmarks.
📋 Key Changes in the Revised Schedule M
- Phased rollout timeline: Large manufacturers must comply by mid-2026; small and medium enterprises (MSMEs) have been granted an extension until later in 2026–2027 (KNN India, December 2025)
- Mandatory bioequivalence (BE) studies: For certain dosage forms, manufacturers must now submit BE data — a first for Indian domestic regulation
- Enhanced quality management systems: Documentation standards now aligned with ICH Q10 guidelines
- Stricter water and air handling systems: ISO-classified clean rooms required for sterile manufacturing
- CDSCO outsourcing GMP audits: The Drugs Controller General of India (DCGI) has instructed state regulators to enforce the new standards, with an expert cadre of approximately 1,500 scientific personnel being built (IndiaMedToday, February 2026)
As reported by Express Pharma and GlobalData (October 2025), the new GMP standards have created some tension between regulators and smaller manufacturers — but the overall direction is toward higher quality and greater global trust in Indian generics.
🔍 How to Verify If a Generic Medicine Is WHO-GMP Compliant
As a buyer or patient, here is a practical checklist to verify the quality of Indian generic medicines before purchasing:
- Check the product packaging — Look for the WHO-GMP logo or a statement like “Manufactured in a WHO-GMP certified facility” on the label or carton
- Verify the manufacturer on CDSCO’s website — The Central Drugs Standard Control Organization maintains a public database of licensed manufacturers. Visit
cdsco.gov.inand check the manufacturer’s license number - Ask for the batch analysis certificate — Reputable manufacturers provide a Certificate of Analysis (CoA) for each batch, which includes purity, potency, and dissolution test results
- Check if the manufacturer is on WHO’s prequalification list — The WHO maintains a list of prequalified manufacturers and products at
extranet.who.int/pqweb - Look for third-party auditor reports — Many WHO-GMP certified facilities are audited by international bodies like the WHO, PIC/S, or national regulatory agencies
For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
🌍 Why WHO-GMP Matters for Global Buyers
For international buyers importing Indian generics — particularly from the United States, Europe, Africa, and Southeast Asia — WHO-GMP certification is more than a label. It is often a regulatory requirement for import clearance.
- US FDA: Requires that generic drug manufacturers pass FDA inspections or demonstrate mutual recognition with WHO-GMP equivalence. India has one of the highest numbers of FDA-registered manufacturing facilities outside the US
- European EMA: Accepts WHO-GMP certification as part of the marketing authorization process for generic drugs sourced from India
- WHO Prequalification: Essential for generic medicines supplied to UN agencies, NGOs, and developing-nation health programs — requires WHO-GMP as a baseline
- African and ASEAN regulators: Many now accept WHO-GMP certification in lieu of domestic inspections, streamlining the import process
✅ Practical Takeaways for Patients and Buyers
To summarize, here is what every buyer of Indian generic medicines should know:
- ✅ India supplies 20% of the world’s generic medicines — scale does not compromise quality under the new Schedule M regime
- ✅ Revised Schedule M (2025-2026) brings Indian GMP standards fully in line with international WHO-GMP norms
- ✅ WHO-GMP certified facilities are audited regularly by internal and external inspectors
- ✅ CDSCO reforms are building a stronger inspection system with 1,500+ expert personnel
- ✅ Bioequivalence requirements for key drug categories ensure generics are therapeutically equivalent to branded counterparts
- ✅ Verified distributors can help you source from WHO-GMP compliant manufacturers
⚕️ Your health depends on the quality of the medicines you take. By understanding WHO-GMP standards and how to verify compliance, you can make informed decisions and access safe, affordable, and effective generic medicines from India.
For more information, contact IMSDA at contact@indiamedicine.org.
Sources: ClearIAS (March 2026), IndiaMedToday (February 2026), KNN India (December 2025), Express Pharma/GlobalData (October 2025), CDSCO official guidelines, WHO Prequalification Program.